JP2016531861A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531861A5
JP2016531861A5 JP2016516904A JP2016516904A JP2016531861A5 JP 2016531861 A5 JP2016531861 A5 JP 2016531861A5 JP 2016516904 A JP2016516904 A JP 2016516904A JP 2016516904 A JP2016516904 A JP 2016516904A JP 2016531861 A5 JP2016531861 A5 JP 2016531861A5
Authority
JP
Japan
Prior art keywords
disease
pi3k
composition
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016516904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531861A (ja
JP6340416B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/057499 external-priority patent/WO2015048318A1/en
Publication of JP2016531861A publication Critical patent/JP2016531861A/ja
Publication of JP2016531861A5 publication Critical patent/JP2016531861A5/ja
Application granted granted Critical
Publication of JP6340416B2 publication Critical patent/JP6340416B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016516904A 2013-09-25 2014-09-25 ホスファチジルイノシトール3−キナーゼ−ガンマの選択的インヒビター Expired - Fee Related JP6340416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361882473P 2013-09-25 2013-09-25
US61/882,473 2013-09-25
PCT/US2014/057499 WO2015048318A1 (en) 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Publications (3)

Publication Number Publication Date
JP2016531861A JP2016531861A (ja) 2016-10-13
JP2016531861A5 true JP2016531861A5 (cg-RX-API-DMAC7.html) 2017-10-05
JP6340416B2 JP6340416B2 (ja) 2018-06-06

Family

ID=51795739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516904A Expired - Fee Related JP6340416B2 (ja) 2013-09-25 2014-09-25 ホスファチジルイノシトール3−キナーゼ−ガンマの選択的インヒビター

Country Status (17)

Country Link
US (1) US10301304B2 (cg-RX-API-DMAC7.html)
EP (2) EP3049415B1 (cg-RX-API-DMAC7.html)
JP (1) JP6340416B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160058950A (cg-RX-API-DMAC7.html)
CN (1) CN105722838B (cg-RX-API-DMAC7.html)
AU (1) AU2014324873B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016006388A2 (cg-RX-API-DMAC7.html)
CA (1) CA2925601C (cg-RX-API-DMAC7.html)
CL (1) CL2016000695A1 (cg-RX-API-DMAC7.html)
ES (2) ES2785053T3 (cg-RX-API-DMAC7.html)
IL (1) IL244742A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016003823A (cg-RX-API-DMAC7.html)
RU (2) RU2675814C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201602265PA (cg-RX-API-DMAC7.html)
UA (1) UA117032C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015048318A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702252B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6786529B2 (ja) * 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ,インコーポレイティド Lpt−723と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
BR112018068075A2 (pt) * 2016-03-10 2019-01-08 Astrazeneca Ab inibidores de fosfatidilinositol 3-quinase gama
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2020210379A1 (en) * 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
AU2020288610A1 (en) 2019-06-04 2022-01-27 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
RU2573569C2 (ru) 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона

Similar Documents

Publication Publication Date Title
RU2016115726A (ru) Селективный ингибитор фосфатидилинозитол-3-киназы-гамма
JP2012521994A5 (cg-RX-API-DMAC7.html)
JP2016540749A5 (cg-RX-API-DMAC7.html)
JP2015514060A5 (cg-RX-API-DMAC7.html)
JP2016516020A5 (cg-RX-API-DMAC7.html)
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
MX2008011369A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2.
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
JP2016507581A5 (cg-RX-API-DMAC7.html)
JP2013528655A5 (cg-RX-API-DMAC7.html)
JP2017514910A5 (cg-RX-API-DMAC7.html)
WO2012048129A3 (en) Inhibitors of polo-like kinase
EA201891143A1 (ru) Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1
CA2796954A1 (en) 7-(1h-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
WO2014143242A8 (en) Compounds useful as inhibitors of atr kinase
MX377387B (es) Nuevo compuesto para usarse en el tratamiento de fibrosis quística.
RU2017121002A (ru) Ингибиторы CD38 и способы лечения
JP2016509051A5 (cg-RX-API-DMAC7.html)
JP2017517512A5 (cg-RX-API-DMAC7.html)
JP2016529306A5 (cg-RX-API-DMAC7.html)
JP2016028076A5 (cg-RX-API-DMAC7.html)
JP2017505809A5 (cg-RX-API-DMAC7.html)
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
JP2015526455A5 (cg-RX-API-DMAC7.html)